Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,887 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma Globotriaosylsphingosine and α-Galactosidase A Activity as a Combined Screening Biomarker for Fabry Disease in a Large Japanese Cohort.
Maruyama H, Taguchi A, Mikame M, Izawa A, Morito N, Izaki K, Seto T, Onishi A, Sugiyama H, Sakai N, Yamabe K, Yokoyama Y, Yamashita S, Satoh H, Toyoda S, Hosojima M, Ito Y, Tazawa R, Ishii S. Maruyama H, et al. Among authors: ito y. Curr Issues Mol Biol. 2021 Jun 19;43(1):389-404. doi: 10.3390/cimb43010032. Curr Issues Mol Biol. 2021. PMID: 34205365 Free PMC article.
Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
Oyama Y, Kazama JJ, Omori K, Higuchi N, Kameda S, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F. Oyama Y, et al. Among authors: ito y. Clin Exp Nephrol. 2005 Jun;9(2):142-7. doi: 10.1007/s10157-005-0342-2. Clin Exp Nephrol. 2005. PMID: 15980949 Clinical Trial.
Abeta-2M-amyloidosis and related bone diseases.
Kazama JJ, Yamamoto S, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F. Kazama JJ, et al. Among authors: ito y. J Bone Miner Metab. 2006;24(2):182-4. doi: 10.1007/s00774-005-0669-5. J Bone Miner Metab. 2006. PMID: 16502130 Review.
Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.
Maruyama H, Taguchi A, Nishikawa Y, Guili C, Mikame M, Nameta M, Yamaguchi Y, Ueno M, Imai N, Ito Y, Nakagawa T, Narita I, Ishii S. Maruyama H, et al. Among authors: ito y. FASEB J. 2018 Aug;32(8):4544-4559. doi: 10.1096/fj.201701374R. Epub 2018 Mar 19. FASEB J. 2018. PMID: 29553830 Free PMC article.
Results demonstrate that mTAL dysfunction causes polyuria and renal impairment and contributes to the pathophysiology of Fabry nephropathy.-Maruyama, H., Taguchi, A., Nishikawa, Y., Guili, C., Mikame, M., Nameta, M., Yamaguchi, Y., Ueno, M., Imai, N., Ito, …
Results demonstrate that mTAL dysfunction causes polyuria and renal impairment and contributes to the pathophysiology of Fabry nephropathy.- …
Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Tsukamoto T, Uchida S, Tsuruya K, Shoji T, Hayashi H, Akai Y, Fukunaga M, Konta T, Nishio S, Goto S, Tamai H, Nagai K, Katafuchi R, Masutani K, Wada T, Nishino T, Shirasaki A, Sobajima H, Nitta K, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Akahori T, Naruse T, Hiramatsu T, Morozumi K, Mimura T, Saka Y, Ishimura E, Hasegawa H, Ichikawa D, Shigematsu T, Sato H, Narita I, Isaka Y; Japan Nephrotic Syndrome Cohort Study investigators. Yamamoto R, et al. J Nephrol. 2022 May;35(4):1135-1144. doi: 10.1007/s40620-022-01279-z. Epub 2022 Apr 2. J Nephrol. 2022. PMID: 35366214
11,887 results
You have reached the last available page of results. Please see the User Guide for more information.